IHL.AX Incannex ASX pre-market 10 Feb 2026: A$0.041 on heavy volume

IHL.AX stock is trading at A$0.041 pre-market on 10 Feb 2026 after a -10.87% one-day move on very heavy 61,360,016 shares. The ASX-listed Incannex Healthcare Limited (IHL.AX) shows extreme intraday interest compared with its 6,427,691.00 average volume, signalling speculative trading ahead of clinical and funding news. At A$14,255,927.00 market cap the company remains a micro-cap biotech in Australia’s healthcare sector, and the pre-market action is the key short-term driver for traders watching product trial milestones and cash runway metrics.

Price action and volume: IHL.AX stock pre-market move

IHL.AX stock opened at A$0.047 and is trading down to A$0.041, with a day range A$0.041–A$0.051 and year range A$0.041–A$0.28. The day’s 61,360,016 shares pushed relative volume to 9.55, far above the 6,427,691.00 average, which typically amplifies volatility for listed micro-caps on ASX.

Valuation and financials: IHL.AX stock metrics

Incannex reports EPS -1.30 and a negative PE reflecting losses; reported PE is -0.03 and price-to-book is 0.75, below the Healthcare sector average PB 5.07, indicating a low asset-price relative to peers. Cash per share is A$0.0217, book value per share A$0.0547, market cap A$14,255,927.00, and current ratio 9.02, which suggests short-term liquidity cover but not profitability.

Clinical pipeline and catalysts: IHL.AX stock news and catalysts

Incannex’s lead programs include IHL-42X (Phase 2/3 for obstructive sleep apnea) and several Phase IIa psychedelic or cannabinoid candidates, which are primary catalysts for share moves. Recent ADR coverage flags trial progress for IHL-42X and has drawn retail interest Investing.com NG. Watch trial readouts and partner announcements as the immediate catalysts ahead of any funding updates Investing.com.

Technical outlook and trading: IHL.AX stock technicals

Price sits under the 50-day average A$0.0649 and 200-day average A$0.10285, marking a downtrend over medium and long terms. The heavy volume spike increases short-term liquidity but raises volatility; traders may use tight stop-losses given the micro-cap structure. For active traders, monitor support at A$0.041 (YTD low) and resistance near A$0.06.

Meyka AI grade and forecast: IHL.AX stock model view

Meyka AI rates IHL.AX with a score out of 100: 65 (Grade B) – HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 12‑month target A$0.075, implying +82.93% upside from the current A$0.041; forecasts are model-based projections and not guarantees. For context, the model balances hefty trial risk with asset-value metrics and cash runway considerations, and we include the company page for real-time data at Meyka IHL.AX page.

Final Thoughts

IHL.AX stock shows clear pre-market stress at A$0.041 on 10 Feb 2026, driven by a -10.87% one-day move and an outsized 61,360,016 share volume. Fundamentals show negative earnings (EPS -1.30) and a negative PE, but a low price-to-book (0.75) and strong current ratio (9.02) give liquidity cover. Key drivers remain clinical trial updates for IHL-42X and other Phase II candidates, plus any funding or partnership news. Meyka AI’s forecast model projects a 12‑month target of A$0.075, implying +82.93% upside versus today’s price of A$0.041; this is a model projection, not a guarantee. Given the micro-cap volatility, we classify this stock as higher risk with event-driven upside if trial readouts or partnerships are positive. Active traders will find volume and volatility attractive in the near term, while longer-term investors need clearer revenue pathways and trial outcomes before raising allocation. Meyka AI — an AI-powered market analysis platform — flags this as a speculative hold with defined catalysts and measurable downside if trials disappoint.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.